FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
Action Follows Confirmatory Trial to Verify Clinical Benefit For Immediate Release: July 06, 2023 Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb),indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit. Leqembi is the first amyloid beta-directed antibody to be converted from […]